

COMPANY OVERVIEW

Avalo Therapeutics, Inc. (AVTX) is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in the areas of Immunology, Immuno-oncology, and Rare Genetic Diseases.

AVALO THERAPEUTICS, INC.

1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087

RECENT NEWS

Avalo to Present at Two Upcoming Conferences

Nov 11 2021, 7:00 AM EST

Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates

Nov 9 2021, 4:01 PM EST

STOCK OVERVIEW

INVESTOR RELATIONS

Symbol	AVTX	ir@avalotx.com
Exchange	Nasdaq	
Market Cap	202.17m	
Last Price	\$1.80	
52-Week Range	\$1.7633 - \$4.50	

12/03/2021 04:00 PM EST

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.